Recent share performance context

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn attention after recent share price moves, with a 1.3% gain over the past day contrasting with declines over the past week, month, and past 3 months.

That mixed performance comes alongside reported annual revenue of US$17.3b and net income of US$1.4b. These figures give investors concrete data to weigh against the current market value of about US$33.5b.

At a share price of US$29.14, Teva’s recent 1 month share price return of a 14.9% decline and 3 month share price return of an 8.2% decline contrast sharply with its 1 year total shareholder return of 85.6%, suggesting longer term momentum from shifting expectations about growth and risk.

If Teva’s moves have caught your eye, this can be a good moment to broaden your watchlist with other healthcare names using a screener focused on 36 healthcare AI stocks

With annual revenue of US$17.3b, net income of US$1.4b and the share price sitting at US$29.14, a key question for investors is whether Teva is still trading at a discount or if the market is already pricing in future growth.

Most Popular Narrative: 23.6% Undervalued

Teva’s most followed narrative pegs fair value at about $38.14 per share versus the last close of $29.14. This frames the current price as a discount built on detailed long term forecasts for revenue, margins, and capital structure.

The analysts have a consensus price target of $23.556 for Teva Pharmaceutical Industries based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $18.0.

Curious how a fair value near $38 sits alongside lower analyst targets, slower forecast revenue growth, and a richer future earnings multiple than the wider pharmaceuticals sector?

Result: Fair Value of $38.14 (UNDERVALUED)

However, this depends on execution, because heavy debt and reliance on a small number of branded drugs leave the story sensitive to setbacks related to the pipeline or pricing.

Another take on valuation

The fair value narrative suggests Teva is 23.6% undervalued at $29.14, yet its 24.1x P/E already sits above the US pharmaceuticals average of 16.5x, the peer average of 20x, and even its own 23.7x fair ratio. That richer multiple raises a simple question: how much upside is the market really leaving on the table?

Next Steps

With mixed signals on value, risk, and reward, the picture is not entirely one sided. Use the full data to pressure test your own take with 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Teva is already on your radar, do not stop there; broaden your opportunity set with curated stock ideas built from robust data and clear fundamentals.

• Spot potential mispricings early by scanning companies highlighted in the 58 high quality undervalued stocks that pair quality fundamentals with attractive valuations.
• Explore potential income streams by checking out the 13 dividend fortresses sourced from businesses offering higher yields alongside stability checks.
• Evaluate resilience by reviewing companies in the 73 resilient stocks with low risk scores that score well on balance sheet strength and earnings consistency.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.